To evaluate if BET inhibition is an effective therapeutic approach for BRCA2-deficient pancreatic cancer in vivo, we subcutaneously injected KPC-mT3 cells into immunocompromised athymic nu/nu mice, and administered either with vehicle or JQ1 (50 mg/kg) via intraperitoneal injection (Fig. 3A). This evidence concerns the gene DNER and familial pancreatic carcinoma.